SCHOLAR ROCK HOLDING CORPORATION Interest Income (Expense), Net
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Interest Income (Expense), Net of $948.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2019-05-15
- SCHOLAR ROCK HOLDING CORPORATION interest income (expense), net for the quarter ending 2019-03-31 was $948.00K, a 558.33% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION interest income (expense), net for the quarter ending 2018-12-31 was $594.00K, a 4850.00% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION interest income (expense), net for the quarter ending 2018-09-30 was $472.00K, a 5144.44% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION interest income (expense), net for the quarter ending 2018-06-30 was $213.00K, a 1836.36% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION interest income (expense), net for fiscal 2018 was $1.42M, a 3131.82% increase from fiscal 2017.
- SCHOLAR ROCK HOLDING CORPORATION interest income (expense), net for fiscal 2017 was $44.00K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2019-03-31 | $948.00K 10-Q · filed 2019-05-15 | $1.54M derived: sum of 2 quarters · filed 2019-05-15 | $2.01M derived: sum of 3 quarters · filed 2019-05-15 | $2.23M derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-12-31 | $594.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $1.07M derived: sum of 2 quarters · filed 2019-03-19 | $1.28M derived: sum of 3 quarters · filed 2019-03-19 | $1.42M 10-K · filed 2019-03-19 |
| 2018-09-30 | $472.00K 10-Q · filed 2018-11-08 | $685.00K derived: sum of 2 quarters · filed 2018-11-08 | $828.00K 10-Q · filed 2018-11-08 | $841.00K derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-06-30 | $213.00K 10-Q · filed 2018-08-08 | $357.00K 10-Q · filed 2018-08-08 | $369.00K derived: sum of 3 quarters · filed 2019-05-15 | $378.00K derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-03-31 | $144.00K 10-Q · filed 2019-05-15 | $156.00K derived: sum of 2 quarters · filed 2019-05-15 | $165.00K derived: sum of 3 quarters · filed 2019-05-15 | $176.00K derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $21.00K derived: sum of 2 quarters · filed 2019-03-19 | $32.00K derived: sum of 3 quarters · filed 2019-03-19 | $44.00K 10-K · filed 2019-03-19 |
| 2017-09-30 | $9.00K 10-Q · filed 2018-11-08 | $20.00K derived: sum of 2 quarters · filed 2018-11-08 | $32.00K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $11.00K 10-Q · filed 2018-08-08 | $23.00K 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |